This phase II trial is trying to understand the effectiveness of immunotherapy (Pembrolizumab) and chemotherapy (Cisplatin/Carboplatin, 5FU) with or without targeted therapy (Evorpacept) in people with head and neck squamous cell carcinoma.
This trial is treating patients with advanced head and neck squamous cell carcinoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment, but your cancer has come back.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
- 21/172 ALX ONCOLOGY - AT148004 - ASPEN-04 - CT1424
A Phase 2 Study of Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
ALX Oncology Inc.
This is a randomised trial with two arms for people with metastatic or unresectable, recurrent head and neck squamous cell carcinoma who have not yet been treated for their advanced disease. In the Experimental Arm, participants will receive Evorpacept (ALX148) + Pembrolizumab + Chemotherapy (Cisplatin/Carboplatin; 5FU). Evorpacept will be administered intravenously (via IV) at a dose of 45mg/kg every three weeks. Pembrolizumab will be administered via IV at a dose of 200mg every three weeks. Chemotherapy will be given every three weeks via IV. In the Active Comparator Arm, participants will receive Pembrolizumab + Chemotherapy. Pembrolizumab will be administered via IV every three weeks at a dose of 200mg. Chemotherapy will be given every three weeks via IV.
Recruiting Hospitals Read More